Impact of Port-A-Cath device management in cancer patients with candidaemia.

Related Articles

Impact of Port-A-Cath device management in cancer patients with candidaemia.

J Hosp Infect. 2012 Dec;82(4):281-5

Authors: Lai YC, Huang LJ, Chen TL, Yang YW, Hsiao LT, Teng HW, Fung CP, Chiou TJ, Tzeng CH, Liu CY

Abstract
This study investigated the impact of management of a totally implantable central venous access port device, Port-A-Cath (Smith Medical, St. Paul, MN, USA), on the outcome of 98 cancer patients with candidaemia. Port-A-Cath retention was found to be significantly associated with poorer outcome, independent of other significant adverse factors [breakthrough candidaemia, Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥ 21, and worse Eastern Cooperative Oncology Group (ECOG) performance score (3-4)]. However, retention of Port-A-Cath devices could be considered in patients who do not have definite catheter-related candidaemia, are not using total parenteral nutrition, do not have poor ECOG performance scores or APACHE II scores, and do not have septic shock.

PMID: 23084483 [PubMed - in process]